Institutional shares held 38.6 Million
834K calls
969K puts
Total value of holdings $529M
$11.4M calls
$13.3M puts
Market Cap $353M
25,757,000 Shares Out.
Institutional ownership 149.69%
# of Institutions 155


Latest Institutional Activity in KROS

Top Purchases

Q2 2025
Adar1 Capital Management, LLC Shares Held: 5.39M ($73.9M)
Q2 2025
Madison Avenue Partners, LP Shares Held: 2.69M ($36.9M)
Q2 2025
Western Standard LLC Shares Held: 1.53M ($21M)
Q2 2025
Jacobs Levy Equity Management, Inc Shares Held: 524K ($7.19M)
Q2 2025
Janus Henderson Group PLC Shares Held: 472K ($6.48M)

Top Sells

Q2 2025
Nuveen, LLC Shares Held: 75.9K ($1.04M)
Q2 2025
Morgan Stanley Shares Held: 879K ($12M)
Q2 2025
Federated Hermes, Inc. Shares Held: 654K ($8.97M)
Q2 2025
Qube Research & Technologies LTD Shares Held: 38.7K ($530K)
Q2 2025
Millennium Management LLC Shares Held: 13.7K ($188K)

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.


Insider Transactions at KROS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.17M Shares
From 13 Insiders
Grant, award, or other acquisition 190K shares
Exercise of conversion of derivative security 49.4K shares
Open market or private purchase 934K shares
Sell / Disposition
1.7K Shares
From 1 Insiders
Exercise of in-the-money or at-the-money derivatives securities 1.7K shares

Track Institutional and Insider Activities on KROS

Follow Keros Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KROS shares.

Notify only if

Insider Trading

Get notified when an Keros Therapeutics, Inc. insider buys or sells KROS shares.

Notify only if

News

Receive news related to Keros Therapeutics, Inc.

Track Activities on KROS